Literature DB >> 26980472

Variations in Receipt of Curative-Intent Surgery for Early-Stage Non-Small Cell Lung Cancer (NSCLC) by State.

Helmneh M Sineshaw1, Xiao-Cheng Wu2, W Dana Flanders3, Raymond Uyiosa Osarogiagbon4, Ahmedin Jemal5.   

Abstract

BACKGROUND: Previous studies reported racial and socioeconomic disparities in receipt of curative-intent surgery for early-stage non-small cell lung cancer (NSCLC) in the United States. We examined variation in receipt of surgery and whether the racial disparity varies by state.
METHODS: Patients in whom stage I or II NSCLC was diagnosed from 2007 to 2011 were identified from 38 state and the District of Columbia population-based cancer registries compiled by the North American Association of Central Cancer Registries. Percentage of patients receiving curative-intent surgery was calculated for each registry. Adjusted risk ratios were generated by using modified Poisson regression to control for sociodemographic (e.g., age, sex, race, insurance) and clinical (e.g., grade, stage) factors. Non-Hispanic (NH) whites and Massachusetts were used as references for comparisons because they had the lowest uninsured rates.
RESULTS: In all registries combined, 66.4% of patients with early-stage NSCLC (73,475 of 110,711) received curative-intent surgery. Receipt of curative-intent surgery for early-stage NSCLC varied substantially by state, ranging from 52.2% to 56.1% in Wyoming, Louisiana, and New Mexico to 75.2% to 77.2% in Massachusetts, New Jersey, and Utah. In a multivariable analysis, the likelihood of receiving curative-intent surgery was significantly lower in all but nine states/registries compared with Massachusetts, ranging from 7% lower in California to 25% lower in Wyoming. Receipt of curative-intent surgery for early-stage NSCLC was lower for NH blacks than for NH whites in every state, although statistically significant in Florida and Texas.
CONCLUSIONS: Receipt of curative-intent surgery for early-stage NSCLC varies substantially across states in the United States, with northeastern states generally showing the highest rates. Further, receipt of treatment appeared to be lower in NH blacks than in NH whites in every state, although statistically significant in Florida and Texas.
Copyright © 2016 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Non–small cell lung cancer; Race; Surgery; Variation

Mesh:

Year:  2016        PMID: 26980472     DOI: 10.1016/j.jtho.2016.03.003

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  10 in total

1.  Disparities in guideline-concordant treatment for node-positive, non-small cell lung cancer following surgery.

Authors:  Norma E Farrow; Selena J An; Paul J Speicher; David H Harpole; Thomas A D'Amico; Jacob A Klapper; Matthew G Hartwig; Betty C Tong
Journal:  J Thorac Cardiovasc Surg       Date:  2019-11-13       Impact factor: 5.209

2.  Use of Positron Emission Tomography Imaging: Another Nonbiological Source of Racial Disparities in US Cancer Care.

Authors:  Aaron P Mitchell; Peter B Bach
Journal:  J Natl Cancer Inst       Date:  2020-12-14       Impact factor: 13.506

3.  Rurality, Stage-Stratified Use of Treatment Modalities, and Survival of Non-small Cell Lung Cancer.

Authors:  Meredith A Ray; Nicholas R Faris; Anna Derrick; Matthew P Smeltzer; Raymond U Osarogiagbon
Journal:  Chest       Date:  2020-05-06       Impact factor: 9.410

4.  The Influence of Physician and Patient Gender on Risk Assessment for Lung Cancer Resection.

Authors:  Mark K Ferguson; Megan Huisingh-Scheetz; Katherine Thompson; Kristen Wroblewski; Jeanne Farnan; Julissa Acevedo
Journal:  Ann Thorac Surg       Date:  2017-04-12       Impact factor: 4.330

5.  Social determinants and facility type impact adherence to best practices in operable IIIAN2 lung cancer.

Authors:  Zaid Muslim; Stephanie Stroever; Mirza Zain Baig; Joanna F Weber; Cliff P Connery; Faiz Y Bhora
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-08-19

6.  Does Race Influence Risk Assessment and Recommendations for Lung Resection? A Randomized Trial.

Authors:  Mark K Ferguson; Carley Demchuk; Kristen Wroblewski; Megan Huisingh-Scheetz; Katherine Thompson; Jeanne Farnan; Julissa Acevedo
Journal:  Ann Thorac Surg       Date:  2018-06-11       Impact factor: 4.330

7.  A system-based intervention to reduce Black-White disparities in the treatment of early stage lung cancer: A pragmatic trial at five cancer centers.

Authors:  Samuel Cykert; Eugenia Eng; Paul Walker; Matthew A Manning; Linda B Robertson; Rohan Arya; Nora S Jones; Dwight E Heron
Journal:  Cancer Med       Date:  2019-02-04       Impact factor: 4.452

8.  Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway.

Authors:  Te Zhang; Wenjie Xia; Xuming Song; Qixing Mao; Xing Huang; Bing Chen; Yingkuan Liang; Hui Wang; Yuzhong Chen; Xinnian Yu; Zeyu Zhang; Wenmin Yang; Lin Xu; Gaochao Dong; Feng Jiang
Journal:  J Hematol Oncol       Date:  2022-08-18       Impact factor: 23.168

9.  Underutilization and disparities in access to EGFR testing among Medicare patients with lung cancer from 2010 - 2013.

Authors:  Julie A Lynch; Brygida Berse; Merry Rabb; Paul Mosquin; Rob Chew; Suzanne L West; Nicole Coomer; Daniel Becker; John Kautter
Journal:  BMC Cancer       Date:  2018-03-20       Impact factor: 4.430

10.  The Role of Race and Economic Characteristics in the Presentation and Survival of Patients With Surgically Resected Non-Small Cell Lung Cancer.

Authors:  John M Varlotto; Kerri McKie; Rickie P Voland; John C Flickinger; Malcolm M DeCamp; Debra Maddox; Paul Stephen Rava; Thomas J Fitzgerald; William Walsh; Paulo Oliveira; Negar Rassaei; Jennifer Baima; Karl Uy
Journal:  Front Oncol       Date:  2018-05-14       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.